DiNardo, C. D., Stein, E. M., Pigneux, A., Altman, J. K., Collins, R., Erba, H. P., … Botton, S. D. (2020). AML-262: Ivosidenib (IVO) Prior to Hematopoietic Cell Transplant (HCT) for Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Who Cannot Tolerate Intensive Chemotherapy (IC). In Clinical Lymphoma Myeloma and Leukemia (Vol. 20, pp. S197–S198). Elsevier BV. https://doi.org/10.1016/s2152-2650(20)30745-x

DiNardo, Courtney D., Eytan M. Stein, Arnaud Pigneux, Jessica K. Altman, Robert Collins, Harry P. Erba, Justin M. Watts, et al. “AML-262: Ivosidenib (IVO) Prior to Hematopoietic Cell Transplant (HCT) for Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Who Cannot Tolerate Intensive Chemotherapy (IC).” In Clinical Lymphoma Myeloma and Leukemia, 20:S197–98. Elsevier BV, 2020. https://doi.org/10.1016/s2152-2650(20)30745-x.

DiNardo CD, Stein EM, Pigneux A, Altman JK, Collins R, Erba HP, et al. AML-262: Ivosidenib (IVO) Prior to Hematopoietic Cell Transplant (HCT) for Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Who Cannot Tolerate Intensive Chemotherapy (IC). In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2020. p. S197–8.

DiNardo, Courtney D., et al. “AML-262: Ivosidenib (IVO) Prior to Hematopoietic Cell Transplant (HCT) for Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Who Cannot Tolerate Intensive Chemotherapy (IC).” Clinical Lymphoma Myeloma and Leukemia, vol. 20, Elsevier BV, 2020, pp. S197–98. Crossref, doi:10.1016/s2152-2650(20)30745-x.

DiNardo CD, Stein EM, Pigneux A, Altman JK, Collins R, Erba HP, Watts JM, Uy GL, Wu B, Choe S, Kapsalis SM, Liu H, Winkler T, Roboz GJ, Botton SD. AML-262: Ivosidenib (IVO) Prior to Hematopoietic Cell Transplant (HCT) for Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Who Cannot Tolerate Intensive Chemotherapy (IC). Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2020. p. S197–S198.